Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001176256-16-000690
Filing Date
2016-11-07
Accepted
2016-11-04 19:19:57
Documents
7
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN ISSUER DATED NOVEMBER 4, 2016 auriniapharma6kq3.htm 6-K 6685
2 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THIRD QUARTER ENDED exhibit99-1.htm EX-99.1 268385
3 MD&A FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2016 exhibit99-2.htm EX-99.2 254631
4 CERTIFICATION OF INTERIM FILINGS - CHIEF EXECUTIVE OFFICER exhibit99-3.htm EX-99.3 9671
5 CERTIFICATION OF INTERIM FILINGS - CHIEF FINANCIAL OFFICER exhibit99-4.htm EX-99.4 11417
6 exhibit99-2x20x1.jpg GRAPHIC 4419
7 exhibit99-3x1x1.jpg GRAPHIC 3970
  Complete submission text file 0001176256-16-000690.txt   563604
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 161976268
SIC: 2834 Pharmaceutical Preparations